Literature DB >> 24184983

Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus.

R Germi1, C Mariette2, S Alain3, J Lupo4, A Thiebaut5, J P Brion2, O Epaulard6, C Saint Raymond7, P Malvezzi8, P Morand4.   

Abstract

Cytomegalovirus (CMV) strains resistant to ganciclovir, cidofovir and/or foscarnet were genotypically and phenotypically characterised in two haematopoietic stem cell transplant recipients and three solid-organ transplant recipients with CMV disease. The anti-malaria drug artesunate led to a favourable virological and clinical response in three cases with mild CMV diseases (fever and neutropaenia) but was ineffective in two fatal CMV diseases with lung involvement in spite of a decrease in the CMV DNA load in blood and bronchoalveolar fluid.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Artesunate; Cytomegalovirus; Multidrug resistance; Transplantation

Mesh：

Substances：

Year:  2013        PMID： 24184983     DOI： 10.1016/j.antiviral.2013.10.014

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


  17 in total

1.  Antiviral effects of artesunate on JC polyomavirus replication in COS-7 cells.

Authors:  Biswa Nath Sharma; Manfred Marschall; Christine Hanssen Rinaldo
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

2.  Inhibition of human cytomegalovirus replication by artemisinins: effects mediated through cell cycle modulation.

Authors:  Sujayita Roy; Ran He; Arun Kapoor; Michael Forman; Jennifer R Mazzone; Gary H Posner; Ravit Arav-Boger
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

3.  Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping.

Authors:  Emilien Drouot; Jocelyne Piret; Marc H Lebel; Guy Boivin
Journal:  J Clin Microbiol       Date:  2014-08-20       Impact factor: 5.948

4.  Emerging cytomegalovirus management strategies after solid organ transplantation: challenges and opportunities.

Authors:  E Beam; V Dioverti; R R Razonable
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

5.  Effect of artemether-lumefantrine (Coartem) on cytomegalovirus urine viral load during and following treatment for malaria in children.

Authors:  Breanna Barger-Kamate; Michael Forman; Cheik Oumar Sangare; Aboubecrin Sedhigh A Haidara; Hamma Maiga; Dhananjay Vaidya; Abdoulaye Djimde; Ravit Arav-Boger
Journal:  J Clin Virol       Date:  2016-02-11       Impact factor: 3.168

6.  How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.

Authors:  Firas El Chaer; Dimpy P Shah; Roy F Chemaly
Journal:  Blood       Date:  2016-10-19       Impact factor: 22.113

Review 7.  Approach to drug-resistant cytomegalovirus in transplant recipients.

Authors:  Sunwen Chou
Journal:  Curr Opin Infect Dis       Date:  2015-08       Impact factor: 4.915

Review 8.  Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation.

Authors:  Ajit P Limaye; Tara M Babu; Michael Boeckh
Journal:  Clin Microbiol Rev       Date:  2020-10-28       Impact factor: 26.132

9.  Inhibition of Cytomegalovirus Replication with Extended-Half-Life Synthetic Ozonides.

Authors:  Yiping Wang; Rupkatha Mukhopadhyay; Sujayita Roy; Arun Kapoor; Yu-Pin Su; Susan A Charman; Gong Chen; Jianbo Wu; Xiaofang Wang; Jonathan L Vennerstrom; Ravit Arav-Boger
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

10.  The Artemisinin Derivative Artemisone Is a Potent Inhibitor of Human Cytomegalovirus Replication.

Authors:  E Oiknine-Djian; Y Weisblum; A Panet; H N Wong; R K Haynes; D G Wolf
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.